FIG. 1



Dosing phase
% Initial Body Weight
120
110
100
90
80
20
40
60
80
Days Post Tumor Implant
Control
Lazertinib
Osimertinib
JNJ-61186372
Lazertinib + JNJ-61186372
Osimertinib + JNJ-61186372

FIG. 2



Dosing phase
2000
1500
1000
500
0
Tumor Volume (mm3)
20
40
60
80
Days Post Tumor Implant
Control
Lazertinib
Osimertinib
JNJ-61186372
Lazertinib + JNJ-61186372
Osimertinib + JNJ-61186372

FIG. 3



Kaplan-Meier Plot for H1975-e286
Percent Remaining
Days
0
10
20
30
40
50
60
70
80
90
100
G1:vehicle / Low Fucose Isotype-CNT(10)ip;biwk x 3
G2:JNJ-70080595(10)po;qd x 21
G3:Osimertinib-CNT(10)po;qd x 21
G4:CNTO4424(10)ip;biwk x 3
G5:JNJ-70080595(10)po;qd x 21 / CNTO4424(10)ip;biwk x 3
G6:Osimertinib-CNT(10)po;qd x 21 / CNTO4424(10)ip;biwk x 3

FIG. 4



Dosing phase
% Initial Body Weight
120
100
80
20
40
60
80
Days Post Tumor Implant
Control
Lazertinib
Osimertinib
JNJ-61186372
Lazertinib + JNJ-61186372
Osimertinib + JNJ-61186372

FIG. 5




2000
1500
1000
500
0
Tumor Volume (mm3)
Dosing phase
20
40
60
80
Days Post Tumor Implant
Control
Lazertinib
Osimertinib
JNJ-61186372
Lazertinib + JNJ-61186372
Osimertinib + JNJ-61186372

FIG. 6


Kaplan-Meier Plot for H1975-HGF-CNT-e205
Percent Remaining
100
80
60
40
20
0
0
10
20
30
40
50
60
70
80
90
Days
G1:vehicle / Low Fucose Isotype-CNT(10)ip;biwk x 3
G2:JNJ-70080595(10)po;qd x 21
G3:Osimertinib-CNT(10)po;qd x 21
G4:CNTO4424(10)ip;biwk x 3
G5:JNJ-70080595(10)po;qd x 21 / CNTO4424(10)ip;biwk x 3
G6:Osimertinib-CNT(10)po;qd x 21 / CNTO4424(10)ip;biwk x 3